Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.51 |
| ▸ | MMP8 | P22894 | 3/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18141994 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL192420 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL1665424 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL17923298 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL15364885 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL5802535 | 1.00 | NAMPT (0.52) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL8092135 | 0.85 | NAMPT (0.65) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL8740549 | 0.85 | NAMPT (0.65) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL3461884 | 0.85 | NAMPT (0.65) | NAMPTMEN1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL2442157 | 0.85 | MEN1 (0.54) | NAMPTMEN1ALDH1A1KMT2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-2920166-B1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| EP-1658067-B1 | INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1658069-B1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
| EP-1658069-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005013981-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NAMPT 2308/4885MEN1 3638/4885ALDH1A1 3388/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NAMPT 2308/4885MEN1 3638/4885ALDH1A1 3388/4885 |
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | PYGL, PYGM, PYGB | NAMPT 1179/4885MEN1 4193/4885ALDH1A1 2417/4885 |
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | NAMPT 921/4885MEN1 2132/4885ALDH1A1 604/4885 |
| US-20080064691-A1 | Heterocyclic Amide Derivatives Which Possess Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | NAMPT 1845/4885MEN1 3606/4885ALDH1A1 3170/4885 |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | NAMPT 2199/4885MEN1 1434/4885ALDH1A1 332/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | NAMPT 2199/4885MEN1 1434/4885ALDH1A1 332/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | NAMPT 929/4885MEN1 2657/4885ALDH1A1 1178/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NAMPT 2308/4885MEN1 3638/4885ALDH1A1 3388/4885 |
| US-20160355521-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NAMPT 2308/4885MEN1 3638/4885ALDH1A1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.